Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine-5'-triphosphate-loaded erythrocytes.
Although HIV-1 and other mammalian lentiviruses infect macrophages, they are not cytopathic. Consequently, these infected long-lived cells serve as major virus reservoirs with a key role in the propagation of the virus throughout the body as well as in the pathogenesis of AIDS. Furthermore, well-differentiated macrophages possess low abilities to phosphorylate the most common reverse transcriptase inhibitors of the nucleoside analog family. In an attempt to overcome these problems we have evaluated in vitro and in vivo in a feline immunodeficiency animal model whether it is possible to protect macrophages from FIV infection by direct administration of dideoxycytidine-5'-triphosphate (ddCTP). Because the cell membranes are impermeable to phosphorylated drugs we have encapsulated ddCTP into autologous erythrocytes. The drug-loaded erythrocyte membranes were then modified to target these carrier cells to macrophages. ddCTP-loaded erythrocytes were able to reduce FIV production by macrophages infected in vitro or obtained from naturally or experimentally infected cats. Furthermore, the administration of ddCTP-loaded erythrocytes protected the majority of peritoneal macrophages during a 7-month experimental FIV infection and reduced the percentage of circulating lymphocytes stained by an anti-p24 antibody. These results suggest that the administration of nucleoside analogs in phosphorylate form is feasible and their targeting to macrophages reduces FIV infection both in vitro and in vivo.
Magnani
M
M
Istituto di Chimica Biologica, Università di Urbino, Italy.
Rossi
L
L
Fraternale
A
A
Silvotti
L
L
Quintavalla
F
F
Piedimonte
G
G
Matteucci
D
D
Baldinotti
F
F
Bendinelli
M
M
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology; D002415:Cats; D002478:Cells, Cultured; D003845:Deoxycytosine Nucleotides / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D054306:Dideoxynucleotides; D004337:Drug Carriers; D004912:Erythrocytes; D016181:Feline Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016089:Immunodeficiency Virus, Feline / Q000187:drug effects / Q000502:physiology*; D008214:Lymphocytes / Q000821:virology; D008264:Macrophages / Q000821:virology*; D009000:Monocytes / Q000821:virology; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D003845:Deoxycytosine Nucleotides; D054306:Dideoxynucleotides; D004337:Drug Carriers; C037406:2',3'-dideoxycytidine 5'-triphosphate